Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. - Wikidata - wikimedia - TriplyDB

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.

http://www.wikidata.org/entity/Q42141882

about

Links between metabolism and cancer Stable isotope-resolved metabolomics and applications for drug development Hypoxia-inducible factors and the response to hypoxic stress Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases Targeting Cancer Metabolism - Revisiting the Warburg Effects Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives Molecular Imaging of Metabolic Reprograming in Mutant IDH Cells Epigenetic regulators and their impact on therapy in acute myeloid leukemia Functions of TET Proteins in Hematopoietic Transformation Dysregulated metabolism contributes to oncogenesis Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation Cerebral neoplasms in L-2 hydroxyglutaric aciduria: 3 new cases and meta-analysis of literature data Concise review: Leukemia stem cells in personalized medicine IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma From fly wings to targeted cancer therapies: a centennial for notch signaling Cancer cell metabolism: implications for therapeutic targets The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases Crystallographic Investigation and Selective Inhibition of Mutant Isocitrate Dehydrogenase Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1 IDH mutations in tumorigenesis and their potential role as novel therapeutic targets.IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis.Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients.IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis.IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma.IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives Undercover: gene control by metabolites and metabolic enzymes Epigenetics in Cancer: A Hematological Perspective Zebrafish and Medaka: new model organisms for modern biomedical research 2-Hydoxyglutarate: D/Riving Pathology in gLiomaS Inhibition of 2-oxoglutarate dependent oxygenases Isocitrate dehydrogenase from Streptococcus mutans: biochemical properties and evaluation of a putative phosphorylation site at Ser102 Single arginine mutation in two yeast isocitrate dehydrogenases: biochemical characterization and functional implication Role of mitochondrial dysfunction in cancer progression Metabolic reprogramming: a cancer hallmark even warburg did not anticipate PII Protein-Derived FRET Sensors for Quantification and Live-Cell Imaging of 2-Oxoglutarate.Rotenone Stereospecifically Increases (S)-2-Hydroxyglutarate in SH-SY5Y Neuronal Cells Oncometabolite D-2-Hydroxyglutarate enhances gene silencing through inhibition of specific H3K36 histone demethylases.WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations.

P2860

Q24626229-C23AE4D1-17B5-493D-82AE-F6D4A083AECF Q24629149-C534FB9E-7FA2-47EA-87B1-C109F82A6578 Q24629323-CBA83FEC-B492-4102-B6DA-3CABCA0B2016 Q24632807-B7FE92E2-1715-473B-8A94-53C4400DCA38 Q26738876-BC01DD89-D7C7-4C3E-B65C-D39B76B67A23 Q26744441-9C8A9706-48F6-483B-8855-034D29BFED53 Q26750861-8D63391B-47F3-4EFB-A16D-8B2104679621 Q26765402-43A84C6B-D962-4B08-BF11-43D11D4260F1 Q26778323-A1ABEB27-E796-43AC-9D8F-B96718A80A7D Q26784630-90282690-D49A-4F0B-8F6B-03D0E91A67A1 Q26822717-625CB839-63C1-4892-BB9A-50FC6365CF47 Q26823896-3E8511B7-1260-4AD8-AD0A-6D5249BC6942 Q26827985-B737E5E8-1E05-4409-ABC7-D4E828DB07F8 Q26995268-520B382D-17B6-4494-B659-686EF3D63831 Q26995506-A46D4685-4391-4697-8AB3-5FA9C206A187 Q27004534-8B67B34A-C0FE-4B46-B707-3A044A92CDBA Q27013632-1292BD29-F72F-41DF-AD76-E72C45E33D44 Q27667409-266122BD-910B-410A-82CD-5E486ED23232 Q27678755-80F9662B-1815-4D6D-9922-DEFD4C90E917 Q27687464-AE9D3BEC-843E-414A-AC8F-A5B45131F58D Q27692015-DB6B8FAB-6A02-4BCF-B7D1-BBF3B7A15B27 Q27851565-71384608-7FD2-4248-AA0E-B70029077ED1 Q27851680-99DAE160-945F-4BF0-BD28-6A21E12FD3DA Q27851701-41B0074B-AEC6-4E5B-AA69-F505740ED07E Q27851805-42DD0624-DA25-4E90-9BB4-DCEF7190CB67 Q27853198-CA40C6FC-C050-4887-B70C-BD88167B5F41 Q28066926-70556016-777D-411E-82E1-99E0516BCA49 Q28072281-9E391147-E269-4F37-9F28-F1A3081C45AD Q28077082-12AA63A3-E325-4785-AD6A-21A069DC742A Q28079758-B9F285DF-7267-46AF-AF73-2F2D73804E91 Q28087807-477C0799-214F-4F77-A69D-7C03E95CA24E Q28306956-06D9E71E-9001-4C24-902D-7DCA5DAC14CB Q28487691-8FE515F4-C9DE-412E-840C-65200D0D57B4 Q28542685-9692D132-82C5-4DCA-AB95-8A2579C14109 Q28829644-7705957B-FE41-4115-8DB1-2A4CFF33A519 Q29617612-DCB54293-21C8-44DC-9563-7B209C867F44 Q29994847-76797813-F853-48B0-9EA7-76A2E6A04FF8 Q33464532-18C7FD41-686C-4AE6-B606-71C682BB32FF Q33554577-EF39FEBB-D5DC-43D2-84DD-BE75EE7CED91 Q33581974-7C365A20-9AF7-48BE-AB08-F594B65E55E8

P2860

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.

http://www.wikidata.org/entity/Q42141882

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Cancer-associated metabolite 2 ...... hydrogenase 1 and 2 mutations.

@en

Cancer-associated metabolite 2 ...... hydrogenase 1 and 2 mutations.

@nl

type

label

Cancer-associated metabolite 2 ...... hydrogenase 1 and 2 mutations.

@en

Cancer-associated metabolite 2 ...... hydrogenase 1 and 2 mutations.

@nl

prefLabel

Cancer-associated metabolite 2 ...... hydrogenase 1 and 2 mutations.

@en

Cancer-associated metabolite 2 ...... hydrogenase 1 and 2 mutations.

@nl

P1433

Q42141882-C3C28A38-4939-48EE-A943-1E19107CB3A3

P1476

Q42141882-07E0B0EC-685B-4EA4-B691-BBDF99C21914

P2093

Q42141882-044040C0-F5A1-4BAD-BC10-36D9AFCCA5E0

Q42141882-14B659A1-B073-47C0-AE58-0C20A1DB2AFA

Q42141882-1886E94F-42ED-42BA-9AEC-9394C8484E87

Q42141882-22D24ED2-BA9A-43A1-85CC-48BD8C003C2B

Q42141882-2411290C-6D59-4080-A765-AD8A1BA40A00

Q42141882-2978E750-2DF4-47E5-9A0B-F3821FE3BA11

Q42141882-33F70224-9963-4BC6-B0FE-AECDF4C5385A

Q42141882-36C71872-7E1F-4658-8F40-98F4654C3E27

Q42141882-3922544E-8DF7-4F3B-916E-AE8DD93C3A5C

Q42141882-594E4B19-07FB-4EEF-9338-4DB4649022B9

P2860

Q42141882-0370CE1A-A674-46BD-BE89-E78035E7E20F

Q42141882-03C955B3-B3FF-410C-BF33-534106A599CA

Q42141882-1BAFF1D7-9A85-4304-A625-34A97EA461E0

Q42141882-1E9401A3-DAB2-470D-B045-8C06EC932209

Q42141882-2F855074-01B0-4C9F-9613-2F08AC9A15A8

Q42141882-40C71A11-F5D4-4F99-897C-955372D71F22

Q42141882-46504D03-47A6-47AB-A44D-200B5F914CB6

Q42141882-4F0BF69E-0560-4B0C-871F-2489C051F517

Q42141882-52880A4A-BB0C-40AF-AF0A-F01879E2E6F6

Q42141882-59C06E92-B312-4A68-84F9-C9AF78EF3189

P304

Q42141882-7B81A8DC-5CEF-485F-A82A-315D73A192D2

P31

Q42141882-B2B64DF5-C10A-47EA-817D-6E30152BE420

P356

Q42141882-54B756C8-DCFE-4B4A-96B7-445747B11AB0

P407

Q42141882-92EEEFF8-CC34-4A0E-A341-2EFC34121CE2

P433

Q42141882-04D68D22-B24B-487D-8F20-043E3A9B10DF

P478

Q42141882-20660FD8-60CE-4461-9547-6EA1D4F3AA16

P577

Q42141882-82109FE0-3B27-4AA1-86FE-1DC3DFAA702B

P5875

Q42141882-B37BF007-087D-4696-BF77-6ECA8BE2A1CA

P698

Q42141882-9F59496C-FE68-45F7-8F74-C40A96ED9F0A

P921

Q42141882-C5714858-E160-4F7A-9116-85FD4175E0A1

P932

Q42141882-EFA307F9-2872-49EB-BDCB-4E9458E6E4DF

P356

P1433

Journal of Experimental Medicine

P1476

Cancer-associated metabolite 2 ...... hydrogenase 1 and 2 mutations.

@en

P2093

David P Schenkein

http://www.w3.org/2001/XMLSchema#string

Edward M Driggers

http://www.w3.org/2001/XMLSchema#string

Hyun Gyung Jang

http://www.w3.org/2001/XMLSchema#string

Lenny Dang

http://www.w3.org/2001/XMLSchema#string

Mark A Bittinger

http://www.w3.org/2001/XMLSchema#string

Mark D Minden

http://www.w3.org/2001/XMLSchema#string

Masato Sasaki

http://www.w3.org/2001/XMLSchema#string

Rob A Cairns

http://www.w3.org/2001/XMLSchema#string

Shengfang Jin

http://www.w3.org/2001/XMLSchema#string

Shinsan M Su

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

Recurring mutations found by sequencing an acute myeloid leukemia genome

An integrated genomic analysis of human glioblastoma multiforme

IDH1 and IDH2 mutations in gliomas

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas

Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.

Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity

Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha

Analysis of the IDH1 codon 132 mutation in brain tumors.

IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors.

P304

339-344

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1084/JEM.20092506

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

207

http://www.w3.org/2001/XMLSchema#string

P577

2010-02-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41416770

http://www.w3.org/2001/XMLSchema#string

P698

20142433

http://www.w3.org/2001/XMLSchema#string

P921

P932

2822606

http://www.w3.org/2001/XMLSchema#string